CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma

Association of CBC-Based Inflammatory Indices With Clinical, Laboratory, and Immunophenotypic Characteristics of Newly Diagnosed Multiple Myeloma

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07823959

Enrollment

Registered

2026-09-17

Start date

2026-10-01

Completion date

2027-11-01

Last updated

2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Multiple Myeloma, Complete Blood Count, Inflammatory Indices, Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, Lymphocyte-to-Monocyte Ratio, Systemic Immune-Inflammation Index, Flow Cytometry, Immunophenotyping

Brief summary

Multiple myeloma is a type of blood cancer characterized by the abnormal growth of plasma cells in the bone marrow. Increasing evidence indicates that interactions between myeloma cells and the host immune-inflammatory response influence disease behavior and patient outcomes. Inflammatory markers calculated from routine complete blood count (CBC) tests, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), offer simple, inexpensive ways to assess systemic inflammation. However, how these markers correlate with baseline clinical presentation, laboratory disease burden, and tumor cell immunophenotypes remains insufficiently explored. The primary purpose of this cross-sectional study is to evaluate the association between CBC-based inflammatory indices and clinical and laboratory measures of disease severity in patients with newly diagnosed multiple myeloma prior to the start of anti-myeloma therapy. The study will also examine the relationship between these inflammatory indices and the specific immunophenotypic characteristics of neoplastic plasma cells identified via bone marrow flow cytometry. A total of 60 patients with newly diagnosed multiple myeloma presenting to Assiut University Hospital and the South Egypt Cancer Institute will be enrolled. Baseline demographic and clinical data (including CRAB manifestations and ISS/R-ISS staging), routine blood laboratory results (including albumin, beta-2 microglobulin, and LDH), bone marrow plasma cell percentages, and flow cytometric findings will be collected and analyzed.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Newly diagnosed Multiple Myeloma patients, evaluated prior to the initiation of anti-myeloma therapy * Both sexes, with no age restriction

Exclusion criteria

* Prior receipt of anti-myeloma treatment * Concurrent active malignancies or other hematological disorders * Presence of acute or chronic inflammatory or infectious conditions that may influence systemic inflammatory indices * Concomitant use of medications that significantly alter inflammatory or hematological parameters

Design outcomes

Primary

Measure	Time frame	Description
Bone Marrow Plasma Cell Percentage	Baseline	The percentage of clonal plasma cells quantified on bone marrow aspirate/biopsy smears at diagnosis. This parameter serves as the primary objective measure of tumor burden and disease severity to evaluate its relationship with baseline complete blood count (CBC)-derived inflammatory indices (specifically the neutrophil-to-lymphocyte ratio \[NLR\]).

Outcome results